Clinical trial

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-01-13

PhasePHASE1

Study timeline

Study start (actual)2021-01-13Date precision: day

Registry last updated2023-04-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Psychotic Disordersunresolved

Mood Disordersunresolved

Schizophrenia Spectrumunresolved

Mental Disordersunresolved

Antipsychotic Agentsunresolved

Tranquilizing Agentsunresolved

Central Nervous System Depressantsunresolved

Physiological Effects of Drugsunresolved

Psychotropic Drugsunresolved

Neurotransmitter Agentsunresolved

Molecular Mechanisms of Pharmacological Actionunresolved

Interventions

LY03010; paliperidone palmitateDRUG

INVEGA SUSTENNADRUG

Sponsors & collaborators

Luye Pharma Group Ltd.lead sponsor

Mapped research locations

ChicagoIllinois, United States1 TorranceCalifornia, United States1 Garden GroveCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04922593 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.